Clathrin Heavy Chain 2/CHC22/CLTCL1 Antibody [Alexa Fluor® 405]

• Reactivity: Hu
• Applications: WB, ICC/IF
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor 405

Clathrin Heavy Chain 2/CHC22/CLTCL1 Antibody [Alexa Fluor® 405] Summary

• Immunogen: E. coli-derived recombinant human Clathrin Heavy Chain 2/CHC22
  Trp1521-Glu1640
  Accession # P53675
• Specificity: Detects human Clathrin Heavy Chain 2/CHC22 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human CHC17 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Clathrin Heavy Chain 2/CHC22/CLTCL1 Antibody [Alexa Fluor® 405]

• CHC22
• Clathrin Heavy Chain 2
• clathrin heavy chain on chromosome 22
• clathrin, heavy chain-like 1
• Clathrin, heavy polypeptide D
• CLH-22
• CLTCL
• CLTCL1
• CLTD
• heavy polypeptide-like 1

Background

CHC22 (clathrin heavy chain on chromosome 22; also Clathrin Heavy Chain 2, CHL-22, CLTCL1, and CLTD) is a 170-190 kDa member of the clathrin heavy chain family of molecules. It is expressed in striated (skeletal and cardiac) muscle and adipocytes. CHC22 appears to participate in glucose transport by interacting with GLUT4 and GGA2, thus contributing to the formation of the GLUT4 storage compartment. CHC22 forms homotrimers, but does not interact with clathrin light chains. Human clathrin heavy chain 2/CHC22 is 1640 amino acids (aa) in length. It contains an N-terminal domain that mediates protein-protein interactions (aa 2-479), a flexible linker region (aa 480-523), a distal segment (aa 524-634), a "proximal" region (aa 639-1640), and a trimerization domain that mediates the formation of a non‑covalent structure (aa 1551-1640). Multiple utilized phosphorylation and acetylation sites exist. There are three potential splice forms. One possesses a seven aa substitution for aa 1620-1640, a second shows a deletion of aa 1479-1535, and a third contains a combination of the afore-mentioned variations. Over aa 1521‑1640, human CHC22 shares 60% aa identity with canine CHC22 and 73% aa identity with human CHC17. In rodent, CHC22 is not expressed as it is represented by a pseudogene.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.